Adding a Second Mutation Did Not Further Delay Cannabinoid Tolerance in Mice

Combining two biological changes does not guarantee an additional effect. A mouse study combining CB1 receptor mutations with deletion of beta-arrestin 2 found no further delay in cannabinoid tolerance beyond the receptor-mutation model alone.

Testing whether mechanisms add together

The investigators compared single- and double-mutant mice with wild-type animals. They tested THC and CP55,940 using antinociception and body-temperature outcomes. The experiment concerned genetically modified animals, not a genetic test for human cannabis impairment.

The pattern depended on drug and sex

The supplied abstract reports delayed tolerance and increased sensitivity to CP55,940 in male single- and double-mutant mice, without the same pattern for THC. Female findings depended on the drug, response and treatment history, and did not show a corresponding difference in tolerance development.

A negative incremental result is informative

If adding a second manipulation does not increase an effect, the result can constrain a proposed mechanism. It does not prove that the second protein has no function in other cells, drugs or conditions. The comparison is about additional effect within the tested models.

These findings also separate initial sensitivity from adaptation during repeated dosing. An animal can respond more strongly to an initial dose without necessarily developing tolerance at a different rate. For forensic use, neither a receptor mechanism nor a tolerance phenotype establishes an individual's preserved driving performance. The practical question remains which compound, function, treatment history and comparison produced the reported result.

Related: interpreting cannabis tolerance claims.

Research cited

Piscura MK; Sepulveda DE; Maulik M; Guindon J; Henderson-Redmond AN; Morgan DJ. Cannabinoid Tolerance in S426A/S430A x β-Arrestin 2 Knockout Double-Mutant Mice. The Journal of pharmacology and experimental therapeutics (2023). doi:10.1124/jpet.122.001367. Findings discussed from the study abstract.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

A Pilot Mouse Study Found Declining THC and CBNA Antinociception With Repeated Administration

A 2021 pilot study reported strong initial antinociceptive responses to THC and cannabinolic acid, followed by decreasing responses over subsequent days. The evidence concerns adult male mice and experimental mechanical and thermal tests. The study evaluated two nociceptive domains Mechanical and thermal responses were assessed after systemic intraperitoneal administration. Those…

Spread the love

Read Article: A Pilot Mouse Study Found Declining THC and CBNA Antinociception With Repeated Administration

Short-Term THC–Morphine Treatment Produced Different Receptor-Protein Patterns in Mouse Midbrain and Spinal Cord

A 2001 mouse study found different opioid- and cannabinoid-receptor protein patterns across midbrain and spinal cord after short-term THC–morphine treatment. A statement about total receptor change would obscure those tissue-specific comparisons. The comparison included separate treatment groups Investigators assessed THC, morphine and their combination using Western blot measurements. Opioid-receptor protein…

Spread the love

Read Article: Short-Term THC–Morphine Treatment Produced Different Receptor-Protein Patterns in Mouse Midbrain and Spinal Cord

A THC Kinase Study Distinguished Reversing Tolerance From Reducing the Initial Drug Effect

A 2003 study found that selected kinase inhibitors reversed THC antinociceptive tolerance while others did not. One higher-dose intervention reduced THC's acute antinociceptive effect, illustrating a different outcome from reversing tolerance. The panel included useful negatives The study tested interventions directed at several kinases. Some did not affect tolerance under…

Spread the love

Read Article: A THC Kinase Study Distinguished Reversing Tolerance From Reducing the Initial Drug Effect

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us